RA Capital Management

RA Capital Management is a Boston-based investment advisor founded in 2004, specializing in the life sciences and healthcare sectors. The firm focuses on early-stage companies developing innovative technologies, products, and services in drug development, medical devices, diagnostics, and research tools. With a team of professionals trained in biology, chemistry, and medicine, RA Capital Management leverages its extensive industry and business development experience to identify and invest in promising healthcare ventures. As a Registered Investment Adviser, the firm employs a strategic approach that includes both venture capital investments and a hedge fund strategy, targeting opportunities primarily in the United States and Europe.

Daniel Bahcheli

Director, Research

Peter Balogh

Analyst

Ryan Berry

Associate

Theresa Cameron

Principal, Strategic Finance

Tess Cameron

Principal

Milind Deshpande

Venture Partner

Derek DiRocco

Partner

Cristina Ghenoiu

Principal

Michael Gillespie MD

Investment Director

Reza Halse

Partner, RA Ventures

Matthew Hammond

Principal

Nathaniel Brooks Horwitz

Principal

Sonia Kartha Ph.D

Ventures Associate

Anurag Kondapalli

Principal

Dan Marks

Venture Senior Associate

Kathryn Meng

Investment Director

David Migl

Analyst

Fuad Naser Ph.D

Analyst

Brigid O'Brien

Managing Partner

Josh Resnick

Senior Managing Director

Prithviraj Roy

Analyst

Zachary Scheiner Ph.D

Principal

Zach Scheiner

Principal

Rajeev Shah

Managing Partner

Rebecca Silberman Ph.D

Investment Director

Jake Simson

Partner

Monica Stanciu Ph.D

Director

Laura Stoppel

Principal

Laura Tadvalkar

Principal

Shan Shan Wang Ph.D

Associate Director

Rajeev Shah

Portfolio Manager and Managing Director

Past deals in South Dakota

SAb Biotherapeutics

Post in 2023
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical development company based in Sioux Falls, South Dakota, with an additional office in Cambridge, Massachusetts. Founded in 2014, the company focuses on developing immunotherapies for various human diseases using its proprietary DiversitAb platform. This innovative platform enables the rapid production of fully targeted human polyclonal antibodies from genetically engineered transchromosomic cattle, eliminating the need for human plasma or serum. SAB Biotherapeutics' product pipeline includes SAB-142 for Type 1 diabetes, SAB-176 for seasonal influenza, and SAB-301 for Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The company's approach aims to address public health challenges, rare diseases, and pandemic threats through advanced antibody science.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.